Brief: Silo Pharma - Commenced Development Of Novel Formulation As Targeted Prophylactic Treatment, Designated As Spc-15, Intended For Stress, Anxiety & PTSD
19/04/2023 14:07
April 19 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA - COMMENCED DEVELOPMENT OF NOVEL FORMULATION
AS
TARGETED PROPHYLACTIC TREATMENT, DESIGNATED AS SPC-15, INTENDED
FOR STRESS, ANXIETY & PTSD
Source text for Eikon: ID:nGNX7mPJp1
Further company coverage: SILO.O
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement